Analysed CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) News Sources
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
22-05-2026
yahoo.com
[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
26-05-2026
yahoo.com
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
02-06-2026
yahoo.com
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
02-06-2026
yahoo.com
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026
04-06-2026
yahoo.com
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
11-06-2026
yahoo.com
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
14-06-2026
yahoo.com
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
14-06-2026
yahoo.com
What is the current price of CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ)?
The current price of CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) is $35.58.
CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) since the previous trading day is $0.58.
CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) since the previous trading day is 1.6571%.
What is the most recent average sentiment score for CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ)?
The most recent average sentiment score for CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ)?
The most recent sentiment for CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ) is .
SEC-8K** Filing Available For CRINETICS PHARMACEUTICALS IN (CRNX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.